Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data

In this paper, the authors provide estimates of 4 measures of vaccine efficacy for live, attenuated and inactivated influenza vaccine based on secondary analysis of 5 experimental influenza challenge studies in seronegative adults and community-based vaccine trials. The 4 vaccine efficacy measures are for susceptibility (VES), symptomatic illness given infection (VEP), infection and illness (VESP), and infectiousness (VEI). The authors also propose a combined (VEC) measure of the reduction in transmission in the entire population based on all of the above efficacy measures. Live influenza vaccine and inactivated vaccine provided similar protection against laboratory-confirmed infection (for live vaccine: VES  = 41%, 95% confidence interval (CI): 15, 66; for inactivated vaccine: VES  = 43%, 95% CI: 8, 79). Live vaccine had a higher efficacy for illness given infection (VEP  = 67%, 95% CI: 24, 100) than inactivated vaccine (VEP  = 29%, 95% CI: −19, 76), although the difference was not statistically significant. VESP for the live vaccine was higher than for the inactivated vaccine. VEI estimates were particularly low for these influenza vaccines. VESP and VEC can remain high for both vaccines, even when VEI is relatively low, as long as the other 2 measures of vaccine efficacy are relatively high.

[1]  A. Langworthy,et al.  An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.

[2]  B. Murphy,et al.  ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTION , 1984, The Lancet.

[3]  B. Murphy,et al.  Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine , 1986, Journal of clinical microbiology.

[4]  B. Murphy,et al.  Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. , 1988, The Journal of infectious diseases.

[5]  B. Murphy,et al.  Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. , 1990, The Journal of infectious diseases.

[6]  M E Halloran,et al.  Epidemiologic effects of vaccines with complex direct effects in an age-structured population. , 1994, Mathematical biosciences.

[7]  F. Hayden,et al.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.

[8]  M E Halloran,et al.  Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. , 1998, Statistics in medicine.

[9]  R. Betts,et al.  Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. , 1999, Vaccine.

[10]  M. Halloran,et al.  Design and interpretation of vaccine field studies. , 1999, Epidemiologic reviews.

[11]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[12]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[13]  M E Halloran,et al.  Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.

[14]  M Elizabeth Halloran,et al.  Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M Elizabeth Halloran,et al.  Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. , 2003, Vaccine.

[16]  H. Chu,et al.  Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. , 2003, American journal of epidemiology.

[17]  C P Farrington,et al.  On vaccine efficacy and reproduction numbers. , 2003, Mathematical biosciences.

[18]  I. Longini,et al.  The critical vaccination fraction for heterogeneous epidemic models. , 2003, Mathematical biosciences.

[19]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[20]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[21]  A. Monto,et al.  Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. , 2006, The New England journal of medicine.

[22]  W. Gruber,et al.  Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections , 2006, The Pediatric infectious disease journal.

[23]  D. Fleming,et al.  Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine-Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care , 2006, Pediatrics.

[24]  M. Halloran,et al.  Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. , 2007, Vaccine.

[25]  R. Walker,et al.  Live attenuated versus inactivated influenza vaccine in infants and young children. , 2007, The New England journal of medicine.

[26]  A. Razmpour,et al.  Efficacy and Safety of a Live Attenuated, Cold-Adapted Influenza Vaccine, Trivalent Against Culture-Confirmed Influenza in Young Children in Asia , 2007, The Pediatric infectious disease journal.

[27]  M. Halloran,et al.  Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. , 2006, American journal of epidemiology.

[28]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.